USA flag logo/image

An Official Website of the United States Government

POTENTIAL BRAIN THERAPEUTICS

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
61174
Program Year/Program:
2002 / SBIR
Agency Tracking Number:
NS043948
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
AMERICAN BIOTECHNOLOGY RESEARCH CORP
AMERICAN BIOTECHNOLOGY RES CORP 424 E STATE PKY, STE 229 SCHAUMBURG, IL 60173
View profile »
Woman-Owned: No
Minority-Owned: Yes
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2002
Title: POTENTIAL BRAIN THERAPEUTICS
Agency: HHS
Contract: 1R44NS043948-01
Award Amount: $187,380.00
 

Abstract:

DESCRIPTION (provided by applicant): Use of botanical products such as exogenous antioxidants has gained considerable momentum in the last few years in therapy of human degenerative diseases. Among these antioxidants, tumeric, neem, guggul, alpha-tocopherol, Beta-carotene, and ascorbic acid have been shown to have a special relevance in maintaining the redox equilibrium in various cell types, including those of the nervous system. They have a strong commercial potential as dietary supplements or as potential pharmaceutical agents in the treatment of various human degenerative diseases. In Phase I of the project, our aim is to develop cell free in vitro assay systems for the measurement of the biological activities of these compounds, using biological molecules present in their free form as targets of reactive oxygen species (ROS). In the development of these methods, we will take into account the critical factors that may influence the results, for example: (a) different types of ROS; (b) different systems for the generation of these ROS; (c) different molecular targets of ROS, and (d) different methods for the measurements of the molecular lesions produced by the ROS. In Phase II of the proposed project, we will optimize assay systems in which the target molecule is present as an integral part of the cell (intact-cell systems). The intact-cell systems will use functional neurons and astrocytes in which the effects of ROS and antioxidants will be measured by their effects on the structural integrity of the mitochondrial DNA. Also, in Phase Il, we will develop an approach for assigning antioxidant indices to mixtures of antioxidants, using a minimum number of different assays.

Principal Investigator:

Anastasios Raptis
8472745618
ANASTRAPTIS@AOL.COM

Business Contact:

Bhavna Vyas
8472745618
BVYASB@AOL.COM
Small Business Information at Submission:

AMERICAN BIOTECHNOLOGY RESEARCH CORP
AMERICAN BIOTECHNOLOGY RES CORP 424 E STATE PKY, STE 229 SCHAUMBURG, IL 60173

EIN/Tax ID: 364459728
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No